相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors
Jenny Ling-Yu Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
Jiali Yu et al.
NATURE MEDICINE (2021)
Radiotherapy-Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery?
Erminia Romano et al.
CANCERS (2021)
Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study
Solmaz Sahebjam et al.
NEURO-ONCOLOGY (2021)
A phase 2 clinical trialassessing theefficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer
Alice Y. Ho et al.
CANCER (2020)
Palliative Liver Radiotherapy (RT) for Symptomatic Hepatocellular Carcinoma (HCC)
Cynthia S. Y. Yeung et al.
SCIENTIFIC REPORTS (2020)
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Michael A. Postow et al.
CLINICAL CANCER RESEARCH (2020)
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Hiro Sato et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678.
Wai Meng David Tai et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
Hailong Sheng et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
Yun Hua Lee et al.
FRONTIERS IN IMMUNOLOGY (2020)
Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial
Yue Hu et al.
FRONTIERS IN ONCOLOGY (2020)
Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study
Yvonne M. Mowery et al.
RADIOTHERAPY AND ONCOLOGY (2019)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T Yau et al.
ANNALS OF ONCOLOGY (2019)
Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy
Chi-Leung Chiang et al.
FRONTIERS IN ONCOLOGY (2019)
Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer
Emmett V. Schmidt
SEMINARS IN IMMUNOPATHOLOGY (2019)
Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
Ruben S. A. Goedegebuure et al.
FRONTIERS IN IMMUNOLOGY (2019)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Silvia C. Formenti et al.
NATURE MEDICINE (2018)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model
Kyoung-Jin Kim et al.
ONCOTARGET (2017)
分享论文
